An epidemiological study has revealed that COVID-19 outcomes are better in those countries that have undertaken a TB vaccination regime in the last 15 years.
Browsing: Bacterial > Tuberculosis
Emerging evidence has suggested that B cells and humoral immunity could modulate the immune response to intracellular pathogens. We speak to Babak Javid about his research on this topic and the importance of learning about immune factors in order to develop vaccination strategies and to understand latent TB.
Administering the BCG vaccine intravenously, as opposed to intradermally, could improve the efficacy of the immunization according to new research in macaque models.
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
New research indicates that harnessing RNA sensors could allow human cells to be more attuned to killing tuberculosis, presenting an effective means for controlling the spread of the disease.
A clinical trial conducted in sub-Saharan African countries over 3 years, has revealed a candidate vaccine for tackling tuberculosis. The candidate vaccine, M72/AS01E, was reported to be 54% effective at preventing active pulmonary tuberculosis disease.
In 2018 more people received treatment for tuberculosis than ever before, largely due to improvements in detection and diagnosis, according to the latest Global Tuberculosis Report from the WHO.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A novel phage-based blood assay has demonstrated its potential for identifying people at high-risk of developing tuberculosis, in addition to diagnosing established cases.